Orleans Capital Management Corp LA Makes New Investment in Gilead Sciences, Inc. $GILD

Orleans Capital Management Corp LA acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,545 shares of the biopharmaceutical company’s stock, valued at approximately $947,000.

A number of other hedge funds have also recently modified their holdings of the stock. Aspire Growth Partners LLC purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $212,000. West Family Investments Inc. lifted its stake in shares of Gilead Sciences by 26.5% in the 2nd quarter. West Family Investments Inc. now owns 12,197 shares of the biopharmaceutical company’s stock valued at $1,352,000 after purchasing an additional 2,558 shares during the period. Loomis Sayles & Co. L P boosted its holdings in Gilead Sciences by 13,018.2% during the second quarter. Loomis Sayles & Co. L P now owns 55,621 shares of the biopharmaceutical company’s stock worth $6,167,000 after buying an additional 55,197 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its position in Gilead Sciences by 12.0% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 2,352,958 shares of the biopharmaceutical company’s stock valued at $260,708,000 after buying an additional 252,108 shares during the period. Finally, Norges Bank purchased a new position in Gilead Sciences in the second quarter valued at $2,150,268,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $125.85 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock’s 50 day simple moving average is $119.87 and its 200-day simple moving average is $114.59. The company has a market cap of $156.13 billion, a PE ratio of 25.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the company earned $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC increased their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Royal Bank Of Canada upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Citigroup raised their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Wolfe Research boosted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Finally, Daiwa Capital Markets increased their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $130.65.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares in the company, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 115,146 shares of company stock worth $14,012,141 in the last quarter. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.